Use of autologous instead of allogeneic blood transfusion during esophagectomy prolongs disease‐free survival among patients with recurrent esophageal cancer
Journal of Surgical Oncology2004Vol. 87(1), pp. 26–31
Citations Over TimeTop 18% of 2004 papers
Satoru Motoyama, Manabu Okuyama, Michihiko Kitamura, Reijiro Saito, Shuichi Kamata, Katsuyuki Murata, Jun‐ichi Ogawa
Abstract
Use of autologous instead of allogeneic blood prolongs disease-free survival of esophageal cancer patients.
Related Papers
- → Optimum Treatment Strategy for Superficial Esophageal Cancer: Endoscopic Mucosal Resection versus Radical Esophagectomy(2001)160 cited
- → The Influence of Different Treatment Strategies on the Long-Term Prognosis of T1 Stage Esophageal Cancer Patients(2021)7 cited
- → Will Patients With Resectable Esophageal Cancer Be Spared Esophagectomy?(2019)1 cited
- An appropriate esophagectomy for esophageal cancer: a lack of evidence and a growing disparity between Western and Eastern standards.(2006)
- → Effect of en bloc esophagectomy and total meso-esophagectomy on esophageal cancer patients: a systematic review and meta-analysis(2022)